Literature DB >> 20127849

An updated follow-up of chronic hepatitis C after three decades of observation in pediatric patients cured of malignancy.

Simone Cesaro1, Flavia Bortolotti, Maria Grazia Petris, Alessandra Brugiolo, Maria Guido, Modesto Carli.   

Abstract

BACKGROUND: The aim of the study was to evaluate the clinical characteristics and the long-term outcome of chronic hepatitis C in a cohort of Caucasian children cured of pediatric malignancy. PROCEDURE: The study population included 83 consecutive patients, referred to our Center with a diagnosis of leukemia/lymphoma (50) or solid tumors (33) between 1977 and 1989 and infected with hepatitis C virus (HCV) during chemotherapy.
RESULTS: At enrollment 77 subjects were HCV-RNA positive. After a median follow-up of 21 years (range 13-36), a sustained virological response (SVR) was obtained in 3 of 29 patients (10%) treated with interferon (IFN), in 1 of 3 patients (33%) treated with IFN and ribavirin, and in 5 of 11 patients (42%) treated with pegylated-IFN and ribavirin (P = 0.03). Forty-two patients remained untreated and only one (2.5%) cleared viremia. Four of 77 patients (5%) developed cirrhosis while other 4 patients died of causes not related to liver. At last follow-up, 72% of HCV-RNA positive patients had abnormal ALT.
CONCLUSIONS: In patients cured of pediatric malignancy chronic hepatitis C tends to run an indolent course during childhood and adolescence but more than 70% of treated and more than 80% of untreated cases children maintained HCV viremia. Moreover, after 2-3 decades of observation, 60% of HCV-RNA positive patients had abnormal ALT and 5% had developed cirrhosis. Among treated patients, IFN or pegylated-IFN and ribavirin obtained the higher rate of HCV-RNA clearance.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20127849     DOI: 10.1002/pbc.22438

Source DB:  PubMed          Journal:  Pediatr Blood Cancer        ISSN: 1545-5009            Impact factor:   3.167


  8 in total

1.  Population pharmacokinetics of peginterferon alfa-2b in pediatric patients with chronic hepatitis C.

Authors:  C Xu; S Gupta; G Krishna; D Cutler; S Wirth; C Galoppo; M Ciocca; K Kolz; S Noviello; V Sniukiene
Journal:  Eur J Clin Pharmacol       Date:  2013-08-24       Impact factor: 2.953

Review 2.  What's new in hepatitis C virus infections in children?

Authors:  Malgorzata Pawlowska; Krzysztof Domagalski; Anna Pniewska; Beata Smok; Waldemar Halota; Andrzej Tretyn
Journal:  World J Gastroenterol       Date:  2015-10-14       Impact factor: 5.742

3.  Long-term follow-up for incident cirrhosis among pediatric cancer survivors with hepatitis C virus infection.

Authors:  Sericea Stallings-Smith; Kevin R Krull; Tara M Brinkman; Melissa M Hudson; Rohit P Ojha
Journal:  J Clin Virol       Date:  2015-07-29       Impact factor: 3.168

4.  Current treatment options and response rates in children with chronic hepatitis C.

Authors:  Stefan Wirth
Journal:  World J Gastroenterol       Date:  2012-01-14       Impact factor: 5.742

5.  Hepatitis C virus infection in mothers and children.

Authors:  Emma Greenaway; Mia J Biondi; Jordan J Feld; Simon C Ling
Journal:  Can Liver J       Date:  2019-12-10

6.  Hematological Adverse events and Sustained Viral Response in Children Undergoing Therapy for Chronic Hepatitis C Infection.

Authors:  Malgorzata Pawlowska; Malgorzata Pilarczyk; Anna Foksinska; Ewa Smukalska; Waldemar Halota
Journal:  Hepat Mon       Date:  2011-12-20       Impact factor: 0.660

Review 7.  Hepatitis C virus infection in children and adolescents.

Authors:  James E Squires; William F Balistreri
Journal:  Hepatol Commun       Date:  2017-03-23

8.  Vertical genotype 1 HCV infection treated successfully in the second year of life: a case report.

Authors:  Małgorzata Pawłowska; Waldemar Halota; Ewa Smukalska
Journal:  Med Sci Monit       Date:  2012-12
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.